Palvella Therapeutics (PVLA) Receivables - Net (2013 - 2024)

Palvella Therapeutics (PVLA) posted quarterly Receivables - Net of $358000.0 for Q4 2024, down 4.02% quarter-over-quarter from $373000.0 in Q3 2024.

Palvella Therapeutics (PVLA) Receivables - Net (2013 - 2024) Analysis & Trends

Palvella Therapeutics (PVLA) has reported Receivables - Net for 11 consecutive years, with $358000.0 the latest figure, recorded in Q4 2024.

In Q4 2024, Receivables - Net changed N/A year-over-year to $358000.0; the TTM figure through Dec 2024 stood at $358000.0 (changed N/A YoY), while the FY2024 annual figure was $358000.0, changed N/A from the prior year.
Receivables - Net fell to $358000.0 in Q4 2024 per PVLA's latest filing, from $373000.0 in the prior quarter.
Across five years, Receivables - Net topped out at $15.8 million in Q1 2021 and bottomed at $358000.0 in Q4 2024.
Historically, Receivables - Net has averaged $3.6 million across 5 years, with a median of $1.7 million in 2020.
Annual changes were most pronounced in 2021 — Receivables - Net jumped 125.75% — and 2022, when it sank 89.6%.
Palvella Therapeutics' Receivables - Net stood at $1.7 million in 2020, then jumped by 94.2% to $3.3 million in 2021, then soared by 75.37% to $5.8 million in 2022, then slumped by 82.01% to $1.0 million in 2023, then tumbled by 65.74% to $358000.0 in 2024.
Business Quant data shows PVLA's Receivables - Net at $358000.0 in Q4 2024, $373000.0 in Q3 2024, and $1.5 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Palvella Therapeutics	2.25 Bn	1.93 Bn	-

Download Data